In this guide
What is Phosphatidylserine?
Phosphatidylserine is a membrane phospholipid. Study products vary by source and co-ingredients, and modest domain-level signals do not establish dementia prevention. No U.S. DRI or established daily requirement exists for supplemental phosphatidylserine. FDA’s qualified cognitive claim reflects limited evidence, not approval to prevent or treat dementia. [2]
Typical Phosphatidylserine Protocols
| Source and population | Form and amount each time | Frequency | Total exposure | Duration or boundary |
|---|---|---|---|---|
| Kang 2022 · 9 studies, 961 older participants | Phosphatidylserine 100–300 mg/day | Study-specific | Usually 300 mg/day in 8 studies | 6 weeks to 6 months |
| Bruton 2021 · 344 children in 4 studies | PS alone or combination products; pooled exposure 200–300 mg/day | Study-specific; exact administration counts varied | 200–300 mg/day in the pooled trials | 3 RCTs (216 children) pooled; low-certainty synthesis |
| Product audit | PS source plus DHA/EPA or phosphatidic acid | Each administration | Calculate every active | Do not transfer combination results to PS alone |
These rows reproduce sources. Do not average them into one universal regimen.
From source to outcome
Small memory-domain signal.
6 weeks to 6 months.
FDA evidence remains limited.
Which forms and label details matter?
Record phosphatidylserine amount, source (soy, sunflower or marine), any DHA/EPA and other phospholipids. Older bovine-brain preparations and modern plant products should not be assumed equivalent.
How should it be stored?
Follow the label, close the container and protect it from heat, light and moisture.
Read the label before the claim
Match the studied preparation.
Keep the daily total visible.
A biomarker is not a clinical event.
What is it commonly used for?
Products target age-related memory, attention, stress and exercise recovery. Cognition findings are modest and heterogeneous; pediatric ADHD evidence is small and low certainty.
What does human research show?
Kang included nine studies and 961 older participants; five RCTs contributed to the memory meta-analysis. PS 100–300 mg/day for six weeks to six months produced a small memory-domain effect, while daily-living ability did not improve. Sources included bovine, soy and marine preparations, and three studies combined PS with DHA/EPA. [1] Bruton identified four pediatric ADHD studies with 344 children and pooled three RCTs with 216 children. At 200–300 mg/day, the small inattention signal was statistically significant, while overall ADHD and hyperactivity-impulsivity results were not; evidence quality was low. This does not establish a routine pediatric regimen. [3] FDA permits only qualified wording for cognitive dysfunction/dementia because evidence remains limited and inconclusive. [2]
How might it act?
Phosphatidylserine is a membrane phospholipid involved in membrane organization and signalling. A plausible cellular role does not show that extra oral PS prevents cognitive decline.
How does it compare with related products?
| Product | Label identity | Practical distinction |
|---|---|---|
| Phosphatidylserine | PS amount, source and formulation | Trial findings remain specific to the tested PS product. |
| Phosphatidylcholine | PC amount and source | Different phospholipid and choline source; not a PS-equivalent dose. |
| Lecithin | Source and phospholipid composition | Variable mixture; lecithin grams do not equal PS grams. |
What are the risks and interactions?
GI upset, headache or insomnia can occur. Review soy or sunflower allergy, anticoagulants, antiplatelets, cholinergic or anticholinergic medicines, pregnancy, breastfeeding and pediatric use. Combination products require a full ingredient review.
Which medicines require review?
Have the product reviewed with medicines, before surgery, and during pregnancy or breastfeeding. No universal separation interval is established.
Regulatory status: In the United States, supplements generally lack premarket efficacy approval. In Canada, verify the finished product’s NPN or DIN-HM and licensed conditions. [4], [5]
What should be monitored?
Record product, lot, form, amount per administration, frequency, daily total, co-ingredients, meals, symptoms, medicines, chosen outcome and review date.
What happens when it is stopped?
No ingredient-specific withdrawal syndrome is established. Record the stop date, symptoms and chosen outcome; seek care for a persistent serious symptom.
Seek prompt care for a serious allergic reaction, unusual bleeding, persistent palpitations, chest pain or another severe symptom.
What do public communities report?
Public reports can suggest questions to track, but they do not verify the product, dose or causality. This update did not newly quantify a community sample.
Common questions about Phosphatidylserine
Does phosphatidylserine prevent dementia?
No. FDA’s qualified claim explicitly reflects limited and inconclusive evidence.
Does it improve memory?
A 2022 synthesis found a small memory-domain effect in older adults, with heterogeneous products.
Does it treat ADHD?
The pediatric evidence is small and low certainty; discuss assessment and standard care.
Is sunflower PS better than soy PS?
Clinical superiority has not been established; source and allergen labeling still matter.
Can DHA-containing PS be treated as PS alone?
No. A combination result stays attached to every active ingredient.
What should I track?
PS amount, source, co-ingredients, administration, cognitive domain, medicines, adverse effects and review date.
Glossary
Terms for reading the evidence.
- ALA
- Essential 18-carbon omega-3; adult AIs refer to this form.
- EPA
- Long-chain omega-3; distinct from total oil weight.
- DHA
- Long-chain omega-3; often present in a different amount from EPA.
- Amount per administration
- Amount consumed at one time, distinct from daily total.
- Biomarqueur
- Biological measure that is not necessarily a clinical benefit.
- UL
- Tolerable Upper Intake Level established for a nutrient and defined scope.
How this guide was researched
Accessible official sources and human reports were read on October 9, 2026. Titles, authors, journals, DOI, PMID and visible corrections were checked. An unreported frequency was not guessed.
How this guide was made
Research and drafting were AI-assisted. This draft awaits Doserly editorial review and independent clinical review. See the editorial policy.
Explore the sources
Sources preserve form, amount, frequency, population, duration and outcome.
Showing 5 sources
- 01
Effect of phosphatidylserine on cognitive function in the elderly ↗
Systematic review and meta-analysis
Current page or report reviewed; scope and limits retained.
Detail: 9 studies, 961 participants, 100–300 mg/day for six weeks to six months.
- 02
Qualified Health Claim: Phosphatidylserine and Cognitive Dysfunction and Dementia ↗
Qualified-claim decision
Current page or report reviewed; scope and limits retained.
Detail: Evidence characterized as limited and inconclusive.
- 03
Phosphatidylserine for the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. ↗
Systematic review and meta-analysis
Current page or report reviewed; scope and limits retained.
Detail: Four studies (344 children); three RCTs (216 children) pooled; 200–300 mg/day and a small low-certainty inattention signal, with overall and hyperactivity-impulsivity results not statistically significant.
- 04
Questions and Answers on Dietary Supplements ↗
U.S. regulatory overview
Current page or report reviewed; scope and limits retained.
Detail: Supplements generally lack efficacy preapproval.
- 05
Product Licensing ↗
Canadian licensing overview
Current page or report reviewed; scope and limits retained.
Detail: Finished natural health products require licensing and authorized labels.
No matching sources
Try a different term or show the full list.